open access

Vol 12, No 3 (2017)
Heart failure
Published online: 2017-06-30
Get Citation

Treatment of acute heart failure

Anna Magdalena Praska-Ogińska, Janusz Bednarski
DOI: 10.5603/FC.2017.0060
·
Folia Cardiologica 2017;12(3):306-316.

open access

Vol 12, No 3 (2017)
Heart failure
Published online: 2017-06-30

Abstract

Acute heart failure (AHF) is a major and growing public health problem worldwide with ten million patients in Europe and
eight hundred thousand patients in Poland. AHF is defined as the rapid onset of, or change in, signs and symptoms of
heart failure (HF) requiring urgent therapy and hospitalization. It arises from a rapid appearance for the first time or as
a result of deterioration in patients with a previous diagnosis of HF. Fast diagnosis and treatment, initially focused on
symptom relief and causal treatment is crucial. This article is the summary of the new European Society of Cardiology
guidelines for the diagnosis and treatment of acute and chronic heart failure and short overview of ongoing multicenter
studies are still lacking on the pharmacotherapy of AHF.

Abstract

Acute heart failure (AHF) is a major and growing public health problem worldwide with ten million patients in Europe and
eight hundred thousand patients in Poland. AHF is defined as the rapid onset of, or change in, signs and symptoms of
heart failure (HF) requiring urgent therapy and hospitalization. It arises from a rapid appearance for the first time or as
a result of deterioration in patients with a previous diagnosis of HF. Fast diagnosis and treatment, initially focused on
symptom relief and causal treatment is crucial. This article is the summary of the new European Society of Cardiology
guidelines for the diagnosis and treatment of acute and chronic heart failure and short overview of ongoing multicenter
studies are still lacking on the pharmacotherapy of AHF.

Get Citation

Keywords

acute heart failure, diuretics, inotropic agents, ularitide, serelaxin

About this article
Title

Treatment of acute heart failure

Journal

Folia Cardiologica

Issue

Vol 12, No 3 (2017)

Pages

306-316

Published online

2017-06-30

DOI

10.5603/FC.2017.0060

Bibliographic record

Folia Cardiologica 2017;12(3):306-316.

Keywords

acute heart failure
diuretics
inotropic agents
ularitide
serelaxin

Authors

Anna Magdalena Praska-Ogińska
Janusz Bednarski

References (41)
  1. Ponikowski P, Voors A, Anker S, et al. Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiologia Polska. 2016; 74(10): 1037–1147.
  2. Dorrance A. Faculty of 1000 evaluation for ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. F1000 - Post-publication peer review of the biomedical literature. .
  3. Gierczyński J, Gryglewicz J, Karczewicz E, Zalewska H. Niewydolność serca — analiza kosztów ekonomicznych i społecznych. Uczelnia Łazarskiego, Warszawa 2013.
  4. Sekcja Niewydolności serca PTK, Niewydolność serca w Polsce — raport 2016. http://www.niewydolnosc-serca.pl/barometr.pdf (22.11.2016).
  5. Sosnowska-Pasiarska B, Bartkowiak R, Wożakowska-Kapłon B, et al. Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). Kardiol Pol. 2013; 71(3): 234–240.
  6. Fonarow GC, Heywood JT, Heidenreich PA, et al. ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007; 153(6): 1021–1028.
  7. The ADHERE (Acute Decompensated Heart Failure National Registry) Registry. Background and Q1 2006 Final Cumulative Benchmark Report. http://www.sciosinc.com/sciosinc/adhere.html.
  8. Gheorghiade M, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006; 296(18): 2217–2226.
  9. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Survey Investigators, Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27(22): 2725–2736.
  10. Bart BA, Goldsmith SR, Lee KL, et al. NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011; 364(9): 797–805.
  11. Felker GM, Teerlink JR. Diagnosis and Management of Acute Heart Failure. In: Mann DL, Zipes DP, Libby P. ed. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 10th edition. Elsevier 2014: 484–493.
  12. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015; 17(6): 544–558.
  13. Straburzyńska-Migaj E, Nessler J. Ostra niewydolność serca w zarysie. Via Medica, Gdańsk 2015.
  14. Zymliński P, Siwołowski P, Biegus J. Ostra niewydolność serca. In: Szczeklik A, Tendera M. ed. Kardiologia. Podręcznik oparty na zasadach EBM, t. II. Medycyna Praktyczna, Kraków 2010: 723–737.
  15. Banaszewski M, Stępińska J. Ostra niewydolność serca. In: Pruszczyk P, Hryniewiecki T, Dróżdż J. ed. Wielka Interna. Kardiologia z elementami angiologii, część II. Medical Tribune Polska, Warszawa 2010: 9–18.
  16. Mizia-Stec K. Układ krążenia. In: Zahorska-Markiewicz B, Małecka-Tendera E. ed. Patofizjologia kliniczna dla studentów medycyny. Volumed, Wrocław 2001: 125–135.
  17. Parol-Baran G. Ostra niewydolność serca — przyczyny, rozpoznanie, postępowanie. In: Repetytorium z kardiologii. Koszyki pytań do egzaminu specjalizacyjnego. Via Medica, Gdańsk 2013: 470–475.
  18. Omar HR, Guglin M. A single BNP measurement in acute heart failure does not reflect the degree of congestion. J Crit Care. 2016; 33: 262–265.
  19. Cosín J, Díez J. TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002; 4(4): 507–513.
  20. Ciurus T, Berner J, Lelonek M. Farmakoterapia ostrej niewydolności serca. Terapia. 2015; 9: 69–75.
  21. Yoshioka K, Matsue Y, Kagiyama N, et al. Recovery from hyponatremia in acute phase is associated with better in-hospital mortality rate in acute heart failure syndrome. J Cardiol. 2016; 67(5): 406–411.
  22. Aljundi AHS, Mohammed SFK, Patel A, et al. Inotropic agents use in patients hospitalized with acute decompensated heart failure: a retrospective analysis from a 22-year registry in a Middle-Eastern Country (1991-2013). BMC Cardiovasc Disord. 2016; 16: 47.
  23. Fonseca C, Araújo I, Marques F, et al. A closer look at acute heart failure: Putting Portuguese and European data into perspective. Rev Port Cardiol. 2016; 35(5): 291–304.
  24. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007; 93(9): 1137–1146.
  25. Channer KS, McLean KA, Lawson-Matthew P, et al. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994; 71(2): 146–150.
  26. Chen HH, Anstrom KJ, Givertz MM, et al. NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013; 310(23): 2533–2543.
  27. Felker GM, Mentz RJ, Adams KF, et al. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. Circ Heart Fail. 2015; 8(5): 997–1005.
  28. Stuart C. FDA puts 30-day limit on tolvaptan for heart failure patients, Cardiovascular Business. www.cardiovascularbusiness.com/topics/heart-failure/fda-puts-30-day-limit-tolvapten-heart-failure-patients (02.12.2016).
  29. Anderson TJ, Meredith IT, Ganz P, et al. Nitric oxide and nitrovasodilators: similarities, differences and potential interactions. J Am Coll Cardiol. 1994; 24(2): 555–566.
  30. Lewis N. Nitroprusside toxicity. Emerg Med. 2000; 32: 71–75.
  31. Felker GM, Hasselblad V, Tang WH, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011; 365(1): 32–43.
  32. Morita Y, Kohsaka S, Oshima K, et al. Use of carperitide infusion for acutely decompensated heart failure. Crit Care. 2012; 16(1): 406.
  33. Biegus J, Zymliński R, Kulej K, et al. Zastosowanie lewosimendanu u chorych z ostrą niewydolnością serca z objawami małego rzutu minutowego serca: opis serii przypadków. Kardiologia Polska. 2013; 71(3): 275–278.
  34. Leczenie ogólne w ostrej niewydolności serca. Termedia. www.termedia.pl/Leczenieogolnewostrejniewydolnosciserca 45,8383,1,0.html (01.09.2016).
  35. Thiele H, Schuler G, Neumann FJ, et al. IABP-SHOCK II Trial Investigators. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J. 2015; 169(4): e7–e8.
  36. Kwong JSW, Yu CM. Ultrafiltration for acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2014; 172(2): 395–402.
  37. http://www.cardiorentis.com/de/rd/true-ahf.php (01.09.2016).
  38. Anker SD, Ponikowski P, Mitrovic V, et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. European Heart Journal. 2015; 36(12): 715–723.
  39. Serelaxin fails to meet primary endpoints in phase 3 RELAX-AHF-2 trial. https://www.escardio.org/The-ESC/Press-Office/Press-releases/serelaxin-fails-to-meet-primary-endpoints-in-phase-3-relax-ahf-2-trial (18.05.2017).
  40. Felker GM, Teerlink JR, Butler J, et al. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. J Am Coll Cardiol. 2014; 64(15): 1591–1598.
  41. Díez J. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions. Am J Cardiovasc Drugs. 2014; 14(4): 275–285.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl